Decoy Therapeutics Inc. SEC filings DCOY
Decoy Therapeutics Inc. has 743 filings in SEC EDGAR's recent list, going back to Aug 6, 2014. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 23, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 16, 2026 | — |
| 424B3 | Prospectus | Oct 16, 2026 | — |
| S-1 | Registration statement | Oct 7, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 23, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 15, 2026 | Sep 14, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| DEF 14A | Proxy statement | Aug 4, 2026 | Sep 14, 2026 |
| DEFA14A | Additional proxy material | Aug 4, 2026 | — |
| 3 | Initial insider ownership | Jul 31, 2026 | Jul 14, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 24, 2026 | Jul 24, 2026 |
| EFFECT | Filing | Jul 17, 2026 | — |
| 424B3 | Prospectus | Jul 17, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
Jul 15, 2026 | Jul 14, 2026 |
| S-1 | Registration statement | Jul 10, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jun 29, 2026 | Jun 26, 2026 |
| EFFECT | Filing | Jun 24, 2026 | — |
| S-1 | Registration statement | Jun 15, 2026 | — |
| RW | Filing | Jun 5, 2026 | — |
| DEFA14A | Additional proxy material | Jun 4, 2026 | — |
| DEF 14A | Proxy statement | Jun 4, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Other events
|
May 19, 2026 | May 19, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 30, 2026 | Dec 31, 2025 |
| S-8 | Employee stock plan registration | Apr 2, 2026 | — |
| 8-K |
Current report
Other events
|
Apr 2, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Feb 25, 2026 | Feb 24, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| DEF 14A | Proxy statement | Jan 9, 2026 | Feb 24, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Listing notice
|
Jan 2, 2026 | Dec 31, 2025 |
| 4 | Insider transaction | Jan 2, 2026 | Dec 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jan 2, 2026 | Dec 31, 2025 |
| PRE 14A | Preliminary proxy statement | Dec 29, 2025 | Feb 24, 2026 |
| DEFA14A | Additional proxy material | Dec 19, 2025 | — |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Dec 19, 2025 | Dec 19, 2025 |
| 4 | Insider transaction | Nov 24, 2025 | Nov 20, 2025 |
| 3 | Initial insider ownership | Nov 24, 2025 | Nov 12, 2025 |
| 3 | Initial insider ownership | Nov 24, 2025 | Nov 12, 2025 |
| 3 | Initial insider ownership | Nov 24, 2025 | Nov 12, 2025 |
| 4 | Insider transaction | Nov 20, 2025 | Nov 20, 2025 |
| 8-K |
Current report
Officer or director change
|
Nov 19, 2025 | Nov 18, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 18, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 17, 2025 | Nov 17, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 14, 2025 | — |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change, Other events
|
Nov 13, 2025 | Nov 11, 2025 |
| 424B4 | Prospectus | Nov 12, 2025 | — |
| FWP | Free writing prospectus | Nov 10, 2025 | — |
| DEFA14A | Additional proxy material | Nov 7, 2025 | — |
| DEF 14A | Proxy statement | Nov 7, 2025 | Dec 31, 2024 |
| S-1/A | Amended registration statement | Oct 21, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Oct 21, 2025 | Oct 21, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 14, 2025 | — |
| 8-K |
Current report
Other events
|
Oct 14, 2025 | Oct 10, 2025 |
| 8-K |
Current report
Other events
|
Oct 6, 2025 | Oct 6, 2025 |
| FWP | Free writing prospectus | Sep 26, 2025 | — |
| S-1/A | Amended registration statement | Sep 23, 2025 | — |
| 8-K |
Current report
Material agreement, Change to shareholder rights
|
Sep 18, 2025 | Sep 17, 2025 |
| 8-K |
Current report
Other events
|
Sep 9, 2025 | Sep 4, 2025 |
| 8-K |
Current report
Other events
|
Aug 27, 2025 | Aug 27, 2025 |
| 8-K |
Current report
Other events
|
Aug 26, 2025 | Aug 22, 2025 |
| 8-K/A | Amended current report | Aug 26, 2025 | Aug 22, 2025 |
| 424B5 | Prospectus supplement | Aug 22, 2025 | — |
| 8-K |
Current report
Other events
|
Aug 22, 2025 | Aug 22, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 18, 2025 | Aug 17, 2025 |
| S-3 | Shelf registration | Aug 15, 2025 | — |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Aug 15, 2025 | Aug 15, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| CORRESP | Letter to the SEC | Aug 11, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| S-1/A | Amended registration statement | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 7, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2025 | — |
| FWP | Free writing prospectus | Aug 5, 2025 | — |
| 8-K |
Current report
Results of operations, Unregistered share sale
|
Jul 31, 2025 | Jul 31, 2025 |
| S-1/A | Amended registration statement | Jul 31, 2025 | — |
| 8-K |
Current report
Material agreement, Change to shareholder rights
|
Jul 29, 2025 | Jul 29, 2025 |
| 8-K |
Current report
Other events
|
Jul 28, 2025 | Jul 28, 2025 |
| 8-K |
Current report
Material agreement, Change to shareholder rights
|
Jul 21, 2025 | Jul 18, 2025 |
| 8-K |
Current report
Other events
|
Jul 14, 2025 | Jul 10, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jul 8, 2025 | Jul 8, 2025 |
| S-1/A | Amended registration statement | Jun 16, 2025 | — |
| 8-K |
Current report
Other events
|
Jun 16, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Material agreement
|
Jun 11, 2025 | Jun 10, 2025 |
| DEFA14A | Additional proxy material | May 27, 2025 | — |
| DEF 14A | Proxy statement | May 27, 2025 | May 27, 2025 |
| CORRESP | Letter to the SEC | May 22, 2025 | — |
| S-1/A | Amended registration statement | May 22, 2025 | — |
| PRE 14A | Preliminary proxy statement | May 15, 2025 | May 15, 2025 |
| DEF 14A | Proxy statement | May 15, 2025 | May 15, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| UPLOAD | Letter from the SEC | May 1, 2025 | — |
| 8-K |
Current report
Listing notice
|
Apr 25, 2025 | Apr 23, 2025 |
| S-1/A | Amended registration statement | Apr 17, 2025 | — |
| CORRESP | Letter to the SEC | Apr 16, 2025 | — |
| 8-K |
Current report
Material agreement, Listing notice
|
Mar 28, 2025 | Mar 26, 2025 |
| 10-K | Annual report | Mar 21, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Other events
|
Mar 11, 2025 | Mar 10, 2025 |
| 424B5 | Prospectus supplement | Mar 11, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 19, 2025 | — |
| S-1 | Registration statement | Jan 21, 2025 | — |
| 8-K |
Current report
Results of operations, Unregistered share sale
|
Jan 17, 2025 | Jan 13, 2025 |
| 424B3 | Prospectus | Jan 13, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Jan 13, 2025 | Jan 10, 2025 |
| EFFECT | Filing | Dec 27, 2024 | — |
| D | Filing | Dec 27, 2024 | — |
| CORRESP | Letter to the SEC | Dec 26, 2024 | — |
| 8-K |
Current report
Shareholder vote results
|
Dec 23, 2024 | Dec 20, 2024 |
| UPLOAD | Letter from the SEC | Dec 18, 2024 | — |
| S-1 | Registration statement | Dec 16, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Dec 13, 2024 | Dec 12, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| DEFA14A | Additional proxy material | Nov 1, 2024 | — |
| DEF 14A | Proxy statement | Nov 1, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Other events
|
Sep 27, 2024 | Sep 27, 2024 |
| 8-K |
Current report
Other events
|
Aug 15, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Other events
|
Aug 14, 2024 | Aug 13, 2024 |
| 10-Q | Quarterly report | Aug 9, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Other events
|
Jul 25, 2024 | Jul 25, 2024 |
| 424B5 | Prospectus supplement | Jul 25, 2024 | — |
| 8-K |
Current report
Other events
|
Jul 23, 2024 | Jul 22, 2024 |
| 424B5 | Prospectus supplement | Jul 22, 2024 | — |
| 8-K |
Current report
Other events
|
Jul 19, 2024 | Jul 19, 2024 |
| 8-K |
Current report
Other events
|
Jul 11, 2024 | Jul 9, 2024 |
| 424B5 | Prospectus supplement | Jun 17, 2024 | — |
| 8-K |
Current report
Other events
|
Jun 17, 2024 | Jun 17, 2024 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Jun 14, 2024 | Jun 14, 2024 |
| 10-Q | Quarterly report | May 13, 2024 | Mar 31, 2024 |
| 10-K/A | Amended annual report | Apr 22, 2024 | Dec 31, 2023 |
| 4 | Insider transaction | Apr 12, 2024 | Apr 11, 2024 |
| DEFA14A | Additional proxy material | Mar 26, 2024 | — |
| DEF 14A | Proxy statement | Mar 26, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Mar 22, 2024 | Dec 31, 2023 |
| DFAN14A | Form dfan14a | Mar 20, 2024 | — |
| PRE 14A | Preliminary proxy statement | Mar 15, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Listing notice
|
Mar 6, 2024 | Mar 5, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Feb 23, 2024 | Feb 20, 2024 |
| 4 | Insider transaction | Feb 22, 2024 | Feb 20, 2024 |
| 4 | Insider transaction | Feb 22, 2024 | Feb 20, 2024 |
| 4 | Insider transaction | Feb 22, 2024 | Feb 20, 2024 |
| 4 | Insider transaction | Feb 22, 2024 | Feb 20, 2024 |
| 4 | Insider transaction | Feb 22, 2024 | Feb 20, 2024 |
| 4 | Insider transaction | Feb 22, 2024 | Feb 20, 2024 |
| 4 | Insider transaction | Feb 22, 2024 | Feb 20, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| SC 13D | Ownership over 5% (active) | Oct 27, 2023 | — |
| 8-K |
Current report
Listing notice
|
Sep 6, 2023 | Sep 5, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Other events
|
Jul 12, 2023 | Jul 11, 2023 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 15, 2023 | Jun 14, 2023 |
| 424B3 | Prospectus | Jun 7, 2023 | — |
| EFFECT | Filing | Jun 6, 2023 | — |
| CORRESP | Letter to the SEC | Jun 2, 2023 | — |
| S-3/A | Filing | Jun 1, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 1, 2023 | — |
| S-3 | Shelf registration | May 26, 2023 | — |
| D | Filing | May 25, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
May 16, 2023 | May 11, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEF 14A | Proxy statement | May 1, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 27, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Other events
|
Mar 13, 2023 | Mar 10, 2023 |
| 4 | Insider transaction | Feb 15, 2023 | Feb 13, 2023 |
| 4 | Insider transaction | Feb 15, 2023 | Feb 13, 2023 |
| S-8 | Employee stock plan registration | Feb 15, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2023 | — |
| 8-K |
Current report
Other events
|
Jan 10, 2023 | Jan 5, 2023 |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| 4/A | Form 4/a | Dec 12, 2022 | Nov 3, 2022 |
| 4/A | Form 4/a | Dec 12, 2022 | Nov 3, 2022 |
| 8-K |
Current report
Other events
|
Dec 1, 2022 | Dec 1, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 4/A | Form 4/a | Nov 8, 2022 | Nov 3, 2022 |
| 4/A | Form 4/a | Nov 8, 2022 | Nov 3, 2022 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DCOY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1615219
- Former names
- Salarius Pharmaceuticals, Inc. (until Jan 9, 2026); Flex Pharma, Inc. (until Jul 22, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.